TABLE 3.
Comparison of disease characteristics by treatment regimen
| Regimen | CPR | FAB/LMB (gr B, C) | EPOCH-R | SC-EPOCH-R | R-only | R-COPAD | R-CHOP | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Total | 13 | 12 | 1 | 2 | 2 | 2 | 1 | 2 | 35 |
| Stage | |||||||||
| I | 1 | 1 | |||||||
| II | 1 | 2 | 1 | 4 | |||||
| III | 9 | 5 | 1 | 1 | 1 | 1 | 1 | 19 | |
| IV | 3 | 5 | 1 | 1 | 1 | 11 | |||
| FAB/LMB risk stratification | |||||||||
| A | 1 | 1 | |||||||
| B | 11 | 9 | 1 | 2 | 1 | 1 | 1 | 1 | 27 |
| C | 2 | 3 | 1 | 1 | 7 | ||||
| Elevated LDH | |||||||||
| Yes | 12 | 11 | 1 | 1 | 1 | 1 | 1 | 1 | 28 |
| No | 1 | 1 | 1 | 1 | 1 | 1 | 7 | ||
| LDH ≥ 2xupper limit of normala | |||||||||
| Yes | 6 | 6 | 1 | 1 | 1 | 1 | 16 | ||
| No | 7 | 6 | 2 | 1 | 1 | 1 | 1 | 19 | |
a
In cases with elevated LDH; CPR, cyclophosphamide, prednisone, rituximab21; EPOCH-R, etoposide, prednisone, vincristine, doxorubicin, cyclophosphamide, and rituximab39,40; FAB/LMB, French-American-British/Lymphomes Malins B8,9,11; LDH, lactate dehydrogenase; R-COPAD, rituximab, cyclophosphamide, vincristine prednisolone and doxorubicin42; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone43; R-only, rituximab only; other: UKCCSG9001 (n = 1),29 POG9317 (n = 1)44; SC-EPOCH-R, short-course EPOCH.27,34